Shearman & Sterling (New York)

Adam S. Hakki

Shearman & Sterling (New York)
Lawyer (Partner)

Adam Hakki is Global Head of Shearman & Sterling’s Litigation Group and an elected member of the firm’s Policy Committee. Adam focuses his practice on both complex litigation and government investigations, with particular focus on class actions, shareholder derivative suits and civil and criminal investigations relating to securities, antitrust, derivatives, commodities and corporative governance issues in courts throughout the US and before the DOJ, SEC, CFTC, FINRA and State AGs. Adam has acted as lead counsel to major financial institutions and asset management firms for the most significant litigations and investigations affecting those industries in recent years. Chambers USA, The Legal 500 and Benchmark Litigation have cited Adam as “the complete package,” “among the most polished and professional litigators in America,” “a force to be reckoned with,” “amazingly bright, with excellent strategic judgment,” having “the rare balance of being incredibly smart and effectively confident,” “a great lawyer with a practical bent that is somewhat rare,” “on top of all of the cutting edge issues,” “very strong with senior management,” “quick, well prepared and responsive,” a “superb writer” “always the most calm and composed person in the room,” “great at making oral presentations,” able to “persuade on his feet,” “having a vast and loyal cadre of investment banks, hedge funds and mutual funds” as clients, “an absolute pleasure to work with,” and a litigator to whom “big banks turn frequently for important matters.”


Lawyer (Partner)

Linked authors

Shearman & Sterling (New York)
Shearman & Sterling (Brussels)
Shearman & Sterling (Washington)
Shearman & Sterling (London)
Shearman & Sterling (Shanghaï)


206 Bulletin

Adam S. Hakki, Beau W. Buffier, Brian G. Burke, Heather Lamberg Kafele, Jerome S. Fortinsky, Richard F. Schwed, Stephen Fishbein, Stephen Mavroghenis The US District Court for the Eastern District of New York awards plaintiffs $162 million in first-ever civil price-fixing verdict against Chinese companies (In re Vitamin C Antitrust Litigation)


On March 14, 2013, a federal jury in Brooklyn, New York returned a verdict in In re Vitamin C Antitrust Litigation, No. 1:06-md-1738 (E.D.N.Y.), finding that two Chinese companies had unlawfully fixed prices and controlled the supply of vitamin C exports from China to the United States. (...)

Send a message